Tatva Chintan Pharma Chem Ltd

Tatva Chintan Pharma Chem Ltd announced credit rating upgrades from CRISIL Ratings Limited, with the Long Term rating upgraded to CRISIL A-/Stable from CRISIL BBB+/Stable and the Short Term rating upgraded to CRISIL A2+ from CRISIL A2; the ratings reflect Fund-Based Facilities (Citibank N. A.) amounting to 85 Crore with a rating of CRISIL A-/Stable, Fund-Based Facilities (State Bank of India) amounting to 40 Crore with a rating of CRISIL A-/Stable, Fund-Based Facilities (ICICI Bank Limited) amounting to 60 Crore with a rating of CRISIL A-/Stable, Fund-Based Facilities (DBS Bank Limited) amounting to 35 Crore with a rating of CRISIL A-/Stable, a Letter of Credit & Bank Guarantee (ICICI Bank Limited) of 5.5 Crore with a rating of CRISIL A2+, a Letter of Credit & Bank Guarantee (State Bank of India) of 5 Crore with a rating of CRISIL A2+, and a Proposed Term Loan of 14.5 Crore with a rating of CRISIL A-/Stable, with no rating actions or withdrawals noted for any of the listed instruments.

Tatva Chintan Pharma Chem Limited informed the BSE Limited and National Stock Exchange of India Limited that its Register of Members and Share Transfer Books will remain closed from September 12, 2026, to September 25, 2026, for the 30th Annual General Meeting scheduled for September 25, 2026, with a record date of September 11, 2026, to determine equity shareholders eligible for the final dividend for Financial Year 2025-26; the company has also fixed September 18, 2026, as the cut-off date for shareholders to vote electronically or attend the AGM.

Tatva Chintan Pharma Chem held the Groundbreaking Ceremony (Bhoomi Pujan) at the new greenfield unit at Dahej - III, Dahej Industrial Estate, Taluka: Vagra, District: Bharuch, Gujarat, India on 20 July 2026.

Shalimar Paints Ltd, Ashima Ltd, Bhansali Engineering Polymers Ltd and Kross Ltd are among the other gainers in the BSE's 'B' group today, 20 July 2026.Tatva Chintan Pharma Chem Ltd surged 19.32% to Rs 1704.45 at 12:01 IST. The stock was the biggest gainer in the BSE's 'B' group. On the BSE, 1.99 lakh shares were traded on the counter so far as against the average daily volumes of 3568 shares in the past one month. Shalimar Paints Ltd soared 15.64% to Rs 57. The stock was the second biggest gainer in 'B' group. On the BSE, 20704 shares were traded on the counter so far as against the average daily volumes of 6276 shares in the past one month. Ashima Ltd spiked 13.75% to Rs 16.38. The stock was the third biggest gainer in 'B' group. On the BSE, 1.35 lakh shares were traded on the counter so far as against the average daily volumes of 11700 shares in the past one month. Bhansali Engineering Polymers Ltd jumped 13.03% to Rs 127.3. The stock was the fourth biggest gainer in 'B' group. On the BSE, 29.9 lakh shares were traded on the counter so far as against the average daily volumes of 56776 shares in the past one month. Kross Ltd spurt 11.14% to Rs 214. The stock was the fifth biggest gainer in 'B' group. On the BSE, 7.83 lakh shares were traded on the counter so far as against the average daily volumes of 17518 shares in the past one month. Powered by Capital Market - Live

The company's consolidated net profit soared 140.3% to Rs 15.98 crore in Q1 FY27, compared with Rs 6.65 crore in Q1 FY26. Revenue from operations jumped 42.95% YoY to Rs 167.05 crore in the quarter ended 30th June 2026. Profit before exceptional items and tax (PBT) increased 118.58% to Rs 15.41 crore in Q1 FY27 from Rs 7.05 crore in Q1 FY26. The company reported exceptional items of Rs 1.31 crore during the quarter. EBITDA climbed 86% YoY to Rs 32.3 crore in Q1 FY27 from Rs 17.3 crore in the year-ago period. EBITDA margin improved to 19% from 15%, reflecting stronger operating performance. During the quarter, Pharmaceuticals and Agrochemicals Intermediates and other Specialty Chemicals (PASC) contributed 35% of total revenue, followed by Structure Directing Agents (SDA) at 34%, Phase Transfer Catalysts (PTC) at 26%, Electrolyte Salts & Solutions (ESS) at 4%, while the remaining 1% came from other products. Segment-wise, revenue from PASC stood at Rs 58.4 crore, SDA at Rs 57.8 crore, PTC at Rs 42.8 crore and ESS at Rs 6.3 crore during the period under review. Tatva Chintan Pharma Chem is primarily engaged in manufacturing, sale and distribution of specialty chemicals, viz., phase transfer catalysts (PTC), structure directing agents (SDA), electrolyte salts and solutions (ESS), pharmaceutical and agrochemical intermediates and other specialty chemicals (PASC).Powered by Capital Market - Live

Net profit of Tatva Chintan Pharma Chem rose 140.30% to Rs 15.98 crore in the quarter ended June 2026 as against Rs 6.65 crore during the previous quarter ended June 2025. Sales rose 42.96% to Rs 167.06 crore in the quarter ended June 2026 as against Rs 116.86 crore during the previous quarter ended June 2025. ParticularsQuarter EndedJun. 2026Jun. 2025% Var. Sales167.06116.86 43 OPM %19.3314.83 - PBDT33.0018.07 83 PBT22.439.10 146 NP15.986.65 140 Powered by Capital Market - Live

Tatva Chintan Pharma Chem will hold a meeting of the Board of Directors of the Company on 17 July 2026.

Tatva Chintan Pharma Chem announced that the Board of Directors of the Company at its meeting held on 16 May 2026, inter alia, have recommended the final dividend of Rs 2 per equity Share (i.e. 20%) , subject to the approval of the shareholders.

Net profit of Tatva Chintan Pharma Chem rose 901.94% to Rs 10.32 crore in the quarter ended March 2026 as against Rs 1.03 crore during the previous quarter ended March 2025. Sales rose 24.36% to Rs 134.14 crore in the quarter ended March 2026 as against Rs 107.86 crore during the previous quarter ended March 2025. For the full year,net profit rose 636.43% to Rs 42.05 crore in the year ended March 2026 as against Rs 5.71 crore during the previous year ended March 2025. Sales rose 32.18% to Rs 505.86 crore in the year ended March 2026 as against Rs 382.71 crore during the previous year ended March 2025. ParticularsQuarter EndedYear EndedMar. 2026Mar. 2025% Var.Mar. 2026Mar. 2025% Var. Sales134.14107.86 24 505.86382.71 32 OPM %20.978.30 -18.428.94 - PBDT26.349.29 184 93.8635.24 166 PBT16.592.03 717 57.017.58 652 NP10.321.03 902 42.055.71 636 Powered by Capital Market - Live

Net profit of Tatva Chintan Pharma Chem rose 720.00% to Rs 9.02 crore in the quarter ended March 2026 as against Rs 1.10 crore during the previous quarter ended March 2025. Sales rose 23.24% to Rs 132.67 crore in the quarter ended March 2026 as against Rs 107.65 crore during the previous quarter ended March 2025. For the full year,net profit rose 11742.42% to Rs 39.08 crore in the year ended March 2026 as against Rs 0.33 crore during the previous year ended March 2025. Sales rose 35.45% to Rs 496.30 crore in the year ended March 2026 as against Rs 366.42 crore during the previous year ended March 2025. ParticularsQuarter EndedYear EndedMar. 2026Mar. 2025% Var.Mar. 2026Mar. 2025% Var. Sales132.67107.65 23 496.30366.42 35 OPM %20.007.35 -18.007.05 - PBDT24.728.82 180 90.0128.11 220 PBT14.971.56 860 53.170.46 11459 NP9.021.10 720 39.080.33 11742 Powered by Capital Market - Live